Curriculum Vitae

Centro de Ciências e Tecnologias Nucleares (C2TN)

Name: Fernanda
Surnames: Marujo Marques
Born: 21-06-1955, Lisbon, Portugal
Nationality: Portuguese

Phone: +351-21 994 6225
Fax: +351-21 994 6185
E-mail: fmarujo [add]


  • 1993 – PhD in Biochemistry, Faculdade de Ciências, Universidade de Lisboa (FCUL).
  • 1978 – Graduate in Chemical Engineering, Instituto Superior Técnico (IST), Universidade de Lisboa.

Professional Employment Career

  • 1994-1998 – Executive Director of Laboratório Central de Análises, Universidade de Aveiro.
  • 1994-......  – Researcher, Instituto Tecnológico e Nuclear (ITN), now IST/CTN.
  • 1985-1994 – Assistant Researcher, Instituto Nacional de Engenharia e Tecnologia Industrial (INETI).
  • 1982-1985 – Trainee Researcher, Laboratório Nacional de Tecnologia Industrial (LNETI).


  • Development of 197/198/199Au gold nanoparticles, in collaboration with University of Columbia Missouri and the MURR reactor group.
  • Cytogenetic Biomarkers in (Radio)Biology. Cytotoxic and genotoxic effects of compounds, in collaboration with Faculdade Ciências Médicas da Universidade Nova de Lisboa.
  • 02/12-09/12/1989 – Development of radioimmunoassays, St. Bartholomews Hospital, London, England and Hungarian Academy of Sciences, Budapest, Hungary.

Membership of Professional Societies

  • Member of the Sociedade Portuguesa de Bioquímica.
  • Member of the Sociedade Portuguesa de Microscopia (SPMicros).

Main Scientific Area of Research

  • Production of Radioisotopes at the Portuguese Research Reactor (RPI).
  • Development of radiopharmaceuticals: synthesis and biological evaluation of radioactive complexes.
  • Biological evaluation of metal-based drugs.

Other Scientific Areas of Interest

  • Biochemistry: transduction mechanisms and hormonal modulation at cellular level.
  • Molecular and Cellular Biology.

Teaching Activities

  • Collaboration in the Master course "Química Inorgânica Biomédica" (ITN-FCUL), 2004-....
  • Collaboration in the Training in Radiopharmacy of Technical Nuclear Medicine Course students, ESTST, Lisbon, 2001-....

Participation in Projects

  • "Preclinical evaluation of ruthenium potential drugs for cancer therapy": PTDC/QUI-QUI/118077/2010 (2012-...).
  • "Synthesis, characterization and biological assessment of multi-functional bone-seeking agents": PTDC/QUI-QUI/115712/2009 (2011-…).
  • "Synthesis and preclinical evaluation of novel estradiol-based In complexes for targeted radiotherapy of tumours": PTDC/QUI-QUI/111891/2009 (2011-…).
  • "Ruthenium complexes for anti-tumour application": PTDC/QUI-QUI/101187/2008 (2010-...).
  • "Chemical, Radiochemical and Biological Studies of Pyrazolyl-Alkylamine Pt(II) Complexes: Application on the Development of Novel Anti-cancer Drugs”: PTDC/QUI/66813/2006 (2008-...).
  • "Novel estrogen receptor ligands as potential probes for targeted tumour imaging and therapy": CIMAGO/FLAD/09/05 (2005-2008).
  • "Multicomponent technetium and gallium metallo-intercalators for targeted radiotherapy": POCTI/QUI/57632/2004.
  • "Radiopharmaceuticals for treatment of bone pain and/or therapy based on macrocyclic lanthanide complexes": POCTI/35859/SAU/99 (2002-2005).
  • "Quality of Skin as a Barrier to Ultra-Fine Particles (NANODERM)": EC Shared COST RTD ACTION: QoL-2002-2004.
  • "Evaluation of the Genotoxic and Antiestrogenic Potential of Triphenylethylene Derivatives and their Metabolites": POCTI/33544/QUI/99 (2000-2004).

Collaborations with other Institutions

  • Laboratório de Genética, Faculdade de Medicina de Lisboa.
  • Instituto Biomédico de Investigação da Luz e Imagem (IBILI), Coimbra.
  • Institute of Advanced Material Study, Kyushu University, Fukuoka, Japan.
  • Departamento de Genética, Faculdade de Ciências Médicas, Universidade Nova de Lisboa.
  • Departamento de Química, Faculdade de Ciências, Universidade do Porto.
  • Departamento de Química, Faculdade de Ciências, Universidade de Lisboa.
  • Instituto de Patologia e Imunologia Molecular (IPATIMUP).
  • Departamento de Química e Laboratório Central de Análises da Universidade de Aveiro.


  •  Prize Ernesto Roma-Boehringer Mannheim (1997) – Portuguese original research work in the area of diabetes mellitus.
  • Drug Discovery & Therapy World Congress 2013, best poster prize 2013.

4 Selected Publications

  • Francisco C, Gama S, Mendes F, Marques F, dos Santos IC, Paulo A, Santos I, Coimbra J, Gabano E, Ravera M. Pt(II) complexes with bidentate and tridentate pyrazolyl-containing chelators: synthesis, structural characterization and biological studies. Dalton Trans. 2011; 40:5781-92. doi: 10.1039/c0dt01785j.
    Journal impact factor:  3.806; citations: 7.
  • Esteves T, Marques F, Paulo A, Rino J, Nanda P, Smith CJ, Santos I. Nuclear targeting with cell-specific multifunctional tricarbonyl M(I) (M is Re, (99m)Tc) complexes: synthesis, characterization, and cell studies. J Biol Inorg Chem. 2011; 16:1141-53. doi: 10.1007/s00775-011-0803-x.
    Journal impact factor:  3.353; citations: 7.
  • Lima LM, Delgado R, Marques F, Gano L, Santos I. TETA analogue containing one methylenephosphonate pendant arm: Lanthanide complexes and biological evaluation of its 153Sm and 166Ho complexes. Eur J Med Chem. 2010; 45:5621-7. doi: 10.1016/j.ejmech.2010.09.013.
    Journal impact factor:  3.849; citations: 3.
  • Neto C, Oliveira MC, Gano L, Marques F, Santos I, Morais GR, Yasuda T, Thiemann T, Botelho F, Oliveira CF. Radioiodinated ligands for the estrogen receptor: effect of different 7-cyanoalkyl chains on the binding affinity of novel iodovinyl-6-dehydroestradiols. Appl Radiat Isot. 2009; 67:301-7. doi: 10.1016/j.apradiso.2008.10.005.
    Journal impact factor:  1.248; citations: 5.

Other Publications

  • "Palladium-109: a new radiocolloid", M. Neves and F. Marques, Int. J. Applied Radiation and Isotopes, 35, 546-547, (1984).
  • "Coupling of a sheep anti-T3 IgG to a solid phase for a triiodotironine radioimmunoassay", I. Santos, F. Marques and L. Patrício, J. Radioanalytical and Nuclear Chemistry, articles 102 143-148, (1986).
  • "Palladium-109 and Holmium-166 potential radionuclides for synoviotherapy-radiation absorbed dose calculations", M. Neves, F. Marques and L. Patrício, Int. J. Applied Radiation and Isotopes, 38, 745-749, (1987).
  • "Holmium-166: a potential lanthanide element in radiotherapy". M. Neves, M. Reis, E. Martinho, F. Marques and L. Patrício, Inorganica Chimica Acta, 140, 359-360, (1987).
  • "Control of NADH ferricyanide reductase activity in the human erythrocyte by somatotrophin and insulin". F. Marques, M. E. Crespo and M. Bicho, Redox Report 1, 113-117, (1995).
  • "Conversion of adrenaline to indolic derivatives by the human erythrocyte plasma membrane". F. Marques, R. O. Duarte, J. J. G. Moura and M. Bicho, Biological Signals, 5, 275-282, (1996).
  • "Insulin activation of NADH ferricyanide reductase in human erythrocytes is mediated by the insulin receptor tyrosine kinase: a comparative study in normal and diabetic states", F. Marques, M. E. Crespo, O. Pantaleão e M. Bicho, Redox Report 2, 373-378, (1996).
  • "Activation of a NADH dehydrogenase in the human erythrocyte by beta-adrenergic agonists: possible involvement of a G protein in enzyme activation". F. Marques and M. P. Bicho, Biological Signals, 6, 52-61, (1997).
  • "Redox modulation of reductase and phosphatase activities in the human erythrocytes". F. Marques, M. E. Crespo, Z. I. Silva and M. Bicho, Protoplasma, 206, 168-173, (1999).
  • "Insulin and high glucose modulation of phosphatase and reductase enzymes in the human erythrocytes. A comparative analysis in normal and diabetic states". F. Marques, M. E. Crespo, Z. I. Silva e M. Bicho, Diabetes Research and Clinical Practice, 47 191-198, (2000).
  • "153Sm and 166Ho complexes with tetraaza macrocycles containing pyridine and methylcarboxylate or methylphosphonate pendant arms". F. Marques, K. P. Guerra, L. Gano, J. Costa, M. P.Campello, L. M .P. Lima, R. Delgado and I. Santos, J. Biol. Inorg. Chem., 9, 859-872, (2004).
  • "Radiopharmaceuticals for targeted radiotherapy". F. Marques, A. Paulo, M. P. Campello, S. Lacerda, R. F. Vitor, L. Gano, R. Delgado and I. Santos, Radiation Protection Dosimetry, 116, 601-604, (2005).
  • "13- and 14- membered macrocyclic ligands containing methylcarboxylate or methylphosphonate pendant arms: chemical and biological evaluation of their 153Sm and 166Ho complexes as potential agents for therapy or bone pain palliation". F. Marques, L. Gano, M. P.Campello, S. Lacerda, I. Santos, L. M. P. Lima, J. Costa, P. Antunes and R. Delgado, J. Inorg. Biochem., 100, 270-280, (2006).
  • "Radiolanthanide complexes with a novel bis(methylphosphonate) tetraazamacrocycle". S. Lacerda, M. P. Campello, F. Marques, L. Gano and I. Santos, Metal Ions in Biology and Medicine 9, 46-51 (2006).
  • "Metal-Based Drugs for Diagnosis and Therapy". S. Alves, R. Vítor, P. D. Raposinho, F. Marques, J. D. G. Correia, A. Paulo, I. Santos, Metal Ions in Biology and Medicine 9, 3-8 (2006).
  • "Radiolanthanide complexes with tetraazamacrocycles bearing methylphosphonate pendant arms as bone seeking agents". L. Gano, F. Marques, M. P. Campello, M. Balbina, S. Lacerda, I. Santos, Q. J. Nucl. Med. Mol. Imaging 51, 6-15 (2007).
  • "Biological evaluation of 153Sm and 166Ho complexes with tetraazamacrocycles containing methylcarboxylate and/or methylphosphonate pendant arms". F. Marques, L. Gano, M. P.Campello, S. Lacerda and I. Santos, Radiochimica Acta 95, 335-41 (2007).
  • "Radiochemical and biological behaviour of 153Sm and 166Ho complexes anchored by a novel bis(methylphosphonate) tetraazamacrocycle". M. P.Campello, F. Marques, L. Gano, S. Lacerda and I. Santos, Radiochimica Acta, 95, 329-34 (2007).
  • "Haemoglobin and erythropoietin levels in polycystic kidney disease". E. A. F. Almeida, I. Alho, F. Marques, C. Thiran, M. P. Bicho, M. Prata., Nephrol. Dial. Transplant. 23, 412-13 (2008).
  • "Chemical and biological evaluation of 153Sm and 166Ho complexes of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylphosphonic acid monoethylester) (H4dotpOEt)" M. Foresterová, Z. Jandurová, F. Marques, L. Gano, P. Lubal, J. Vanek, P. Hermann, I. Santos. J. Inorg. Biochem. 102, 1531-40 (2008).
  • "A novel tetraazamacrocycle bearing a thiol pendant arm for labeling biomolecules with radiolanthanides" Lacerda S, Campello MP, Marques F, Gano L, Kubícek V, Fousková P, Tóth E, Santos, I.Dalton Trans. 21, 4509-18 (2009).
  • "Pyrazolyl-diamine ligands thar bear anthacenyl moieties and rhenium(I) tricarbonyl complexes: synthesis, characterization and DNA-binding properties". R. F. Vitor, I. Correia, M. Videira, F. Marques, A. Paulo, J. C. Pessoa, G. Viola, G. G. Martins,I. Santos. ChemBioChem 9, 131-42 (2008).
  • "99mTc-tricarbonyl complexes functionalized with anthracenyl fragments: synthesis, characterization, and evaluation of their radiotoxic effects in murine melanoma cells" Vitor R. F.,Esteves T., Marques F., Raposinho P., Paulo A., Rodrigues S., Rueff J., Casimiro S., Costa L., Santos I. Cancer Biother. Radiopharm. 24, 551-63 (2009).
  • "Tricarbonyl M(I) (M=Re, 99mTc) complexes bearing acridine fluorophores: synthesis, characterization, DNA interaction studies and nuclear targeting". T. Esteves, C. Xavier, S. Gama, F. Mendes, P. Raposinho, F. Marques, A. Paulo, J. C. Pessoa, J. Rino, G. Viola, I. Santos. Org. Biomol. Chem. 8, 4104-16 (2010).
  • "Synthesis, characterization and cytotoxic activity of gallium(III) complexes anchored by tridentate pyrazole-based ligands". F. Silva, F. Marques, I. C. Santos, A. Paulo, A. S. Rodrigues, J. Rueff, I. Santos. J. Inorg. Biochem. 104, 523-32 (2010).
  • "Copper (II) complexes with tridentate pyrazole-based ligands: synthesis, characterization, DNA cleavage activity and cytotoxicity". S. Gama, F. Mendes, F. Marques, I. C. Santos, M. F. Carvalho, I. Correia, J. C. Pessoa, I. Santos. J. Inorganic Biochemistry 105, 637-644 (2011).
  • "Searching for gallium bioactive compounds: Gallium(III) complexes of tridentate alicylaldehyde se-micarbazone derivatives". Gambino D, Fernández M, Santos D, Etcheverría GA, Piro OE, Pavan FR, Leite CQF, Tomaz I, Marques F. Polyhedron 30, 1360–1366 (2011).
  • "Synthesis and biological studies of pyrazolyl-diamine Pt(II) complexes containing polyaromatic DNA-binding groups". Gama S., Mendes F., Esteves T., Marques F., Matos A., Rino J., Coimbra J., Ravera M., Gabano E., Santos I., Paulo A. Chembiochem. 13, 2352-62 (2012).
  • "Estrogen Receptor Ligands for Targeting Breast Tumours: A Brief Outlook on Radioiodination Strategies". Oliveira M.C., Neto C., Gano L., Marques F., Santos I., Thiemann T., Santos A.C., Botelho F., Oliveira C.F., Curr Radiopharm. 5, 124-41 (2012).
  • "Novel estradiol based complexes of Tc-99m". Neto C., Oliveira M.C., Gano L., Marques F., Thiemann T., Santos I. J Inorg Biochem. 111, 1-9 (2012).
  • "Novel 7a-alkoxy-17a-(4'-halophenylethynyl)estradiols as potential SPECT/PET imaging agents for estrogen receptor expressing tumours: synthesis and binding affinity evaluation". Neto C, Oliveira MC, Gano L, Marques F, Yasuda T, Thiemann T, Kniess T, Santos I. Steroids. 77, 1123-32 (2012).
  • "Synthesis of organometallic ruthenium(II) complexes with strong activity against several human cancer cell lines". Morais TS, Silva TJ, Marques F, Robalo MP, Avecilla F, Amorim Madeira PJ, Mendes PJ, Santos I, Garcia MH. J Inorg Biochem. 114, 65-74 (2012).
  • "[RuII(?5-C5H5)(bipy)(PPh3)]?, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin. Tomaz AI, Jakusch T, Morais TS, Marques F, de Almeida RF, Mendes F, Enyedy EA, Santos I, Pessoa JC, Kiss T, Garcia MH. J Inorg Biochem. 117, 261-9 (2012).
  • "Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism". Demoro B, de Almeida RF, Marques F, Matos CP, Otero L, Costa Pessoa J, Santos I, Rodríguez A, Moreno V, Lorenzo J, Gambino D, Tomaz AI. Dalton Trans. 42, 7131-46 (2013).
  • "New bifunctional metalloproteinase inhibitors: an integrated approach towards biological improvements and cancer therapy". Marques S.M., Abate C.C., Chaves S., Marques F., Santos I., Nuti E., Rossello A., Santos M.A. J Inorg Biochem. 127, 188-202. (2013).
  • "Biological activity and cellular uptake of [Ru(eta5-C5H5)(PPh3)(Me2bpy)][CF3SO3] complex". Morais T.S., Santos F., Côrte-Real L., Marques F., Robalo M.P., Madeira P.J., Garcia M.H. J Inorg Biochem. 122, 8-17 (2013).
  • "New polydentate Ru(III)-Salan complexes: Synthesis, characterization, anti-tumour activity and interaction with human serum proteins". Matos C.P., Valente A., Marques F., Adão P., Robalo M.P., Almeida R.M., Pessoa J.C., Santos I., Garcia, M.H., Tomaz A.I. Inorganica Chimica Acta 394, 616–626 (2013).
  • "Cellular Uptake Mechanisms of an Antitumor Ruthenium Compound: The Endosomal/Lysosomal System as a Target for Anticancer Metal-Based Drugs". Côrte-Real L., Matos A.P., Alho I., Morais T.S., Tomaz A.I., Garcia M.H., Bicho M.P., Marques F. Microsc. Microanal. 19, 1–9 (2013).
  • "First polymer ruthenium-cyclopentadienyl complex as potential anticancer agent". Valente A, Garcia MH, Marques F, Miao Y, Rousseau C, Zinck P. J Inorg Biochem. 127C, 79-81 (2013).
  • "Important cytotoxicity of novel iron(II) cyclopentadienyl complexes with imidazole based ligands". Gonçalves A.C., Morais T.S., Robalo M.P., Marques F., Avecilla F., Matos C.P., Santos I., Tomaz A.I., Garcia M.H. J Inorg Biochem. 129, 1–8 (2013).